109 related articles for article (PubMed ID: 8031168)
1. [Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)].
Sakata Y; Suzuki H; Kamataki T
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1241-4. PubMed ID: 8031168
[TBL] [Abstract][Full Text] [Related]
2. [Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].
Mori K; Hirose T; Machida S; Tominaga K
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1159-63. PubMed ID: 9679578
[TBL] [Abstract][Full Text] [Related]
3. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
Mori K; Kondo T; Kamiyama Y; Kano Y; Tominaga K
Cancer Chemother Pharmacol; 2003 May; 51(5):403-6. PubMed ID: 12687289
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat.
Kase Y; Hayakawa T; Aburada M; Komatsu Y; Kamataki T
Jpn J Pharmacol; 1997 Dec; 75(4):407-13. PubMed ID: 9469647
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
[TBL] [Abstract][Full Text] [Related]
6. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
[TBL] [Abstract][Full Text] [Related]
8. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
[TBL] [Abstract][Full Text] [Related]
9. [CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].
Kanbe M; Osada M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2145-7. PubMed ID: 16352947
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Abigerges D; Armand JP; Chabot GG; Da Costa L; Fadel E; Cote C; Hérait P; Gandia D
J Natl Cancer Inst; 1994 Mar; 86(6):446-9. PubMed ID: 8120919
[TBL] [Abstract][Full Text] [Related]
11. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Karthaus M; Ballo H; Abenhardt W; Steinmetz T; Geer T; Schimke J; Braumann D; Behrens R; Behringer D; Kindler M; Messmann H; Boeck HP; Greinwald R; Kleeberg U
Oncology; 2005; 68(4-6):326-32. PubMed ID: 16020959
[TBL] [Abstract][Full Text] [Related]
12. [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Ota K; Ohno R; Shirakawa S; Masaoka T; Okada K; Ohashi Y; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1047-55. PubMed ID: 8210256
[TBL] [Abstract][Full Text] [Related]
13. [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].
Sakata Y; Shimada Y; Yoshino M; Kambe M; Futatsuki K; Nakao I; Ogawa N; Wakui A; Taguchi T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1039-46. PubMed ID: 8210255
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ
J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383
[TBL] [Abstract][Full Text] [Related]
15. Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.
Maeda Y; Ohune T; Nakamura M; Yamasaki M; Kiribayashi Y; Murakami T
Oncol Rep; 2004 Sep; 12(3):581-5. PubMed ID: 15289841
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
[TBL] [Abstract][Full Text] [Related]
17. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
[TBL] [Abstract][Full Text] [Related]
18. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1171-7. PubMed ID: 12145998
[TBL] [Abstract][Full Text] [Related]
19. The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.
Chowbay B; Sharma A; Zhou QY; Cheung YB; Lee EJ
Oncol Rep; 2003; 10(3):745-51. PubMed ID: 12684653
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
de Forni M; Bugat R; Chabot GG; Culine S; Extra JM; Gouyette A; Madelaine I; Marty ME; Mathieu-Boué A
Cancer Res; 1994 Aug; 54(16):4347-54. PubMed ID: 8044782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
